Treace Medical Concepts (TMCI) Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology

PONTE VEDRA, Fla. — Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a pioneer in medical technology focused on enhancing the surgical treatment of bunions and related midfoot deformities, has successfully completed its first surgical case using the innovative Lapiplasty® Lightning™ technology. This cutting-edge technology builds upon Treace's acclaimed Lapiplasty® System, introducing advanced instrumentation aimed at reducing the number of surgical steps and improving correction accuracy across all three planes of motion.

Enhancements in Surgical Efficiency

The Lapiplasty® Lightning™ technology not only simplifies procedural workflows bolstered by Treace's SpeedPlate® Rapid Compression Fixation technology but also emphasizes Treace's commitment to advancing surgical precision. John T. Treace, CEO and Chairman of the Company, remarked, “As the pioneers and leaders in instrumented 3D bunion correction, Lightning technology demonstrates our dedication to enhancing our patented Lapiplasty® System, which ultimately expands its appeal to a greater number of surgeons."

Treace anticipates rolling out a limited market release of the Lapiplasty® Lightning™ System by mid-2026, with full commercialization expected by the end of the year.

Surgeon Insights on Lightning Technology

Dr. William T. DeCarbo, DPM, of the Greater Pittsburgh Foot & Ankle Center and a member of Treace’s Surgeon Advisory Board, performed the inaugural procedure using the new Lightning technology. He noted, “Lightning integrates years of clinical insights and feedback, allowing for a faster Lapiplasty® procedure while enhancing accuracy and control during the 3-plane correction. The instrumentation's ability to maintain correction throughout the case, eliminating the need for provisional fixation, greatly simplifies my surgical workflow.”

Forward-Looking Statements

This announcement includes forward-looking statements as defined by the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements concern expectations regarding the timing of the Lapiplasty® Lightning™ System’s limited market release and full commercialization. Actual financial performance may differ significantly due to various factors, as detailed in Treace’s public filings with the Securities and Exchange Commission (SEC).

About Treace Medical Concepts

Treace Medical Concepts, Inc. is dedicated to setting new standards in the surgical management of bunions and related midfoot deformities affecting approximately 67 million Americans. Annually, around 1.1 million individuals are potential surgical candidates. The company has developed and patented the Lapiplasty® 3D Bunion Correction® System that offers comprehensive solutions for correcting all three planes of the bunion deformity. Furthermore, Treace supports surgical needs through its Adductoplasty® Midfoot Correction System and minimally invasive solutions like the Nanoplasty® 3D System.